Kapadi — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Kapadi is a privately held, US-based oncology CRO founded in 2020, positioning itself as an industry leader for complex trials in immuno-oncology and cell & gene therapy. Its core value proposition combines decades of operational experience with advanced technological and data analytics solutions, a historic connection to Moffitt Cancer Center for scientific guidance, and a global site network for patient access. The company is revenue-generating, offering tailored services to biotech clients navigating the challenging landscape of modern cancer drug development.

Oncology

Technology Platform

Integrated clinical trial management platform featuring real-time data analytics, risk analysis/mitigation tools, and technological solutions tailored for complex oncology and cell & gene therapy trials.

Opportunities

The rapid growth in cell & gene therapy and immuno-oncology development creates strong demand for specialized CRO services.

Kapadi's global site network and strategic partnership with Moffitt Cancer Center provide a competitive edge in patient access and scientific credibility for these complex trials.

Risk Factors

Kapadi faces intense competition from large, global CROs and other niche players.

Its reliance on the volatile biotech sector for clients makes it susceptible to downturns in R&D funding.

Execution risks in managing highly complex and risky trials could impact its reputation.

Competitive Landscape

Kapadi competes in the oncology CRO segment against large, full-service CROs (e.g., IQVIA, ICON) and smaller, specialized oncology CROs. Its differentiation is its deep, exclusive focus on oncology/IO/CGT, its Moffitt Cancer Center partnership, and its integrated technology platform designed for complex trials.

More companies in Oncology (General) →More companies in United States →